Journal Mobile Options
Table of Contents
Vol. 16, No. 5, 2009
Issue release date: June 2009
Neuroimmunomodulation 2009;16:353–362
(DOI:10.1159/000216193)

Intranasal Corticosteroids and Adrenal Suppression

Bruni F.M. · De Luca G. · Venturoli V. · Boner A.L.
Departments of Pediatrics,aPoliclinico G.B. Rossi, Verona, and bBentivoglio Hospital, Bologna, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Allergic rhinitis is a common condition that frequently coexists with asthma and atopic dermatitis. It is commonly treated with intranasal corticosteroids which may increase the potential inception of side effects of the same type of drugs used for the treatment of other allergic diseases. A method to assess the systemic effect of corticosteroids is the evaluation of their effect on the hypothalamic-pituitary-adrenal (HPA) axis. However, it is not clear which test is best for detection of clinically relevant HPA axis suppression in children Morning plasma cortisol levels are twice that of late afternoon and evening values and a delay in the time of onset in peak cortisol levels has been observed in children treated with inhaled corticosteroids. Single morning cortisol level has a low sensitivity for detecting adrenal insufficiency in children. 24-Hour plasma cortisol is a good test because it is a non-invasive measure of the biologically active free cortisol levels for the entire day. For research purposes, the 24-hour integrated concentration plasma cortisol test is preferred. Studies that have looked at HPA axis suppression with intranasal corticosteroids indicate that overall, intranasal corticosteroids have a minimal effect on the HPA axis. A review of the literature reveals one study in which there was a decreased output of urinary cortisol during treatment with either budesonide or fluticasone propionate in adults. Other studies with fluticasone propionate or budesonide have shown no effect on the HPA axis in children. Beclomethasone dipropionate was shown to affect urinary cortisol output in one study on healthy volunteers. However, in a long-term study in children, no effect on the HPA axis was found. Mometasone furoate has been extensively studied in more than 20 trials of adults and children. No effects on the HPA axis were detected in either children or adults. Fluticasone furoate nasal spray was not associated with HPA axis suppression. It is unlikely that children are more sensitive to corticosteroids than adults. There is no reason to perform routine monitoring of adrenal function in children who are treated with intranasal corticosteroid unless those drugs are used concomitantly with inhaled corticosteroids and/or steroid ointments for the possible concomitant presence of asthma and/or atopic dermatitis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mygind N: Glucocorticosteroids and rhinitis. Allergy 1993;48:476–490.
  2. Toogood JH, Jennings B, Crepea SB, Johnson JD: Efficacy of safety of concurrent use of intranasal flunisolide and oral beclomethasone aerosols in treatment of asthmatics with rhinitis. Clin Allergy 1982;12:95–105.
  3. Kamada AK, Parks DP, Szefler SJ: Inhaled glucocorticoid therapy in children: how much is safe? Pediatr Pulmonol 1992;12:71–72.
  4. Orth DN, Kovacs WJ: The adrenal cortex; in Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds): Williams Textbook of Endocrinology. Philadelphia, Saunders, 1998, pp 517–664.
  5. Dempsey OJ, Wilson AM, Coutie WJ, Lipworth BJ: Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999;116:935–940.
  6. Allen DB: Sense and sensitivity: assessing inhaled corticosteroid effects on the hypothalamic-pituitary-adrenal axis. Ann Allergy Asthma Immunol 2002;89:537–539.
  7. Bernstein DI, Allen DB: Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007;98:118–127.
  8. Law CM, Marchant JL, Honour JW, Preece MA, Warner JO: Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate [published erratum appears in Lancet 1987;6:1321]. Lancet 1986;1:942–944.
  9. Stewart PM, Corrie J, Seckl JR, Edwards CR, Padfield PL: A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet 1988;1:1208–1210.
  10. Holt PR, Lowndes DW, Smithies E, Dixon GT: The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis: which tests should be used? Clin Exp Allergy 1990;20:145–149.
  11. Lipworth BJ, Seckl JR: Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997;52:476–482.
  12. Honour JW: Hypothalamic-pituitary-adrenal axis. Respir Med 1994;88(suppl A):9–15.
  13. Prahl P, Jensen T, Bjerregaard-Andersen H: Adrenocortical function in children on high-dose steroid aerosol therapy: results of serum cortisol, ACTH stimulation test and 24-hour urinary free cortical excretion. Allergy 1987;42:541–544.
  14. Brown PH, Blundell G, Greening AP, Crompton GK: Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 1991;85:511–516.
  15. McIntyre HD, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowley DM: Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24-hour specimens. Thorax 1995;50:1280–1284.
  16. Chalew SA, Zadik Z, McCarter R, Kowarski AA: Hypocortisolemia in children undergoing evaluation for growth hormone deficiency. J Clin Endocrinol Metab 1990;71:952–957.
  17. Zadik Z, De Lacerda L, De Carmargo LA, Hamilton BP, Migeon CJ, Kowarski AA: A comparative study of urinary 17-hydroxycorticosteroids, urinary free cortisol, and the integrated concentration of plasma cortisol. J Clin Endocrinol Metab 1980;51:1099–1101.
  18. Phillip M, Aviram M, Leiberman E, et al: Integrated plasma cortisol concentration in children with asthma receiving long-term inhaled corticosteroids. Pediatr Pulmonol 1992;12:84–89.
  19. Cunningham SK, Moore A, McKenna TJ: Normal cortisol response to corticotropin in patients with secondary adrenal failure. Arch Intern Med 1983;143:2276–2279.
  20. Broide J, Soferman R, Kivity S, et al: Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995;80:1243–1246.
  21. Wilson AM, McFarlane LC, Lipworth BJ: Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998;101:470–474.
  22. Wilson AM, McFarlane LC, Lipworth BJ: Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab 1998;83:922–925.
  23. Schlaghecke R, Kornely E, Santen RT, Ridderskamp P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992;326:226–230.
  24. Sherman B, Weinberger M, Chen-Walden H, Wendt H: Further studies of the effects of inhaled glucocorticoids on pituitary-adrenal function in healthy adults. J Allergy Clin Immunol 1982;69:208–212.
  25. Staub JJ, Noelpp B, Girard J, Baumann JB, Graf S, Ratcliffe JG: The short metyrapone test: comparison of the plasma ACTH response to metyrapone and insulin-induced hyperglycaemia. Clin Endocrinol 1979;10:595–601.
  26. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronnegard M: Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 1995;144:301–310.
  27. Howland WC III: Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 1996;26(suppl 3):18–22.
  28. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R: Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274–282.
  29. Sheth KK, Cook CK, Philpot EE, et al: Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc 2004;25:115–120.
  30. Ratner PH, Paull BR, Findlay SR, et al: Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice-daily. J Allergy Clin Immunol 1992;90:285–291.
  31. Grossman J, Banov C, Bronsky EA, et al: Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993;92:594–599.
  32. Fluticasone Propionate Collaborative Pediatric Working Group: Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 1994;125:628–634.
  33. Galant SP, Melamed IR, Nayak AS, et al: Lack of effect of FP aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003;112:96–100.
  34. Synnerstad B, Lindqvist N: A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12-month study. Br J Clin Pract 1996;50:363–366.
  35. Lindqvist N, Balle VH, Karma P, et al: Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis: a 12-month multicentre study. Allergy 1986;41:179–186.
  36. Wihl JA, Andersson KE, Johansson SA: Systemic effects of two nasally administered glucocorticosteroids. Allergy 1997;52:620–626.
  37. Agertoft L, Wolthers OD, Fuglsang G, Pedersen S: Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993;4:152–156.
  38. Kim KT, Rabinovitch N, Uryniak T, et al: Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 2004;93:61–67.
  39. Wurthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381–394.
  40. Edelman DA, Van Os WAA: Safety of intranasal beclomethasone dipropionate: a review. Respir Care 1996;11:1025–1030.
  41. Fireman P: A comparison of intranasal beclomethasone dipropionate with other agents in the treatment of rhinitis: a review of published clinical experience. Todays Ther Trends 1991;9:21–34.
  42. Rachelefsky G, Chervinsky P, Meltzer E, et al: An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ (VNS)) on long-term growth in children. J Allergy Clin Immunol 1998;101(suppl):S236.
  43. Kokron CM, Castro AS, Sole D, Naspitz CK: Lysine-vasopressin in the evaluation of the hypothalamic-pituitary-adrenal axis in children with allergic rhinitis treated with intranasal beclomethasone dipropionate or oral prednisone. J Investig Allergol Clin Immunol 1997;7:51–56.
  44. Skoner DP, Rachelefsky GS, Meltzer EO: Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23.
  45. Kwaselow A, McLean J, Busse W, et al: A comparison of intranasal and oral flunisolide in the therapy of allergic rhinitis: evidence for a topical effect. Allergy 1985;40:363–367.
  46. Howland WC III, Dockhorn R, Gillman S, et al: A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. J Allergy Clin Immunol 1996;98:32–38.
  47. Welch MJ, Bronsky E, Findlay S, et al: Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis. Clin Ther 1994;16:253–262.
  48. Feiss G, Morris R, Rom D, et al: A comparative study of the effects of intranasal triamcinolone acetonide aerosol and prednisone on adrenocortical function. J Allergy Clin Immunol 1992;89:1151–1156.
  49. Tinkelman D, Falliers C, Gross G, et al: Multicenter evaluation of triamcinolone acetonide nasal aerosol in the treatment of adult patients with seasonal allergic rhinitis. Ann Allergy 1990;64:234–240.
  50. Lipworth BJ, Wilson AM: Twenty-four-hour adrenocortical profiles in asthmatics receiving inhaled and intranasal corticosteroids. J Allergy Clin Immunol 1998;101:S8.

    External Resources

  51. Nayak AS, Ellis MH, Gross GN, et al: The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998;101:157–162.
  52. Bachert C, Lukat KF, Lange B: Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin Exp Allergy 2004;34:85–90.
  53. Patel D, Ratner P, Clements D, et al: Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol 2008;100:490–496.
  54. Davies RJ, Nelson HS: Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997;19:27–38; discussion 22–23.
  55. Brannan M, Seiberling M, Cutler D, Cuss F, Affrime M: Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol 1996;97:198.

    External Resources

  56. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ: Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598–604.
  57. Brannan MD, Herron JM, Affrime MB: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997;19:1330–1339.
  58. Meltzer EO, Berger WE, Berkowitz RB, et al: A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:107–114.
  59. Schenkel E, Skoner D, Bronsky E, et al: Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:e22.
  60. Zitt M, Kosoglou T, Hubbell J: Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317–326.
  61. Kimmerle R, Rolla AR: Iatrogenic Cushing’s syndrome due to dexamethasone nasal drops. Am J Med 1985;79:535–537.
  62. Perry RJ, Findlay CA, Donaldson MD: Cushing’s syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 2002;87:45–48.
  63. Harrison BD, Rees LH, Cayton RM, Nabarro JD: Recovery of hypothalamo- pituitary-adrenal function in asthmatics whose oral steroids have been stopped or reduced. Clin Endocrinol (Oxf) 1982;17:109–118.
  64. Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:S1–S53.
  65. Derendorf H, Mollmann H, Hochhaus G, et al: Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther 1997;35:481–488.
  66. Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga O: Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987;31:579–582.
  67. Pedersen S: Efficacy and safety of inhaled corticosteroids in children; in Schleimer RP et al (eds): Inhaled Glucocorticoids in Asthma. New York, Dekker, 1997, pp 551–606.
  68. Meltzer EO: Treatment options for the child with allergic rhinitis. Clin Pediatr (Phila) 1998;37:1–10.
  69. Allen ED, Whitaker ER, Ryu G: Six-week trial of nebulized flunisolide nasal spray: efficacy in young children with moderately severe asthma. Pediatr Pulmonol 1997;24:397–405.
  70. Medical Control Agency: The safety of inhaled and nasal corticosteroids. The Pink-Sheet, 1998.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50